Company News: AstraZeneca and Astra Tech

Share this article:

AstraZeneca has put its Astra Tech dental implant and medical device unit on the block for about $2 billion, various news outlets reported. The sale price reflects 3.4 times the Swedish division's earnings, according to a Reuters report. JP Morgan Chase has been hired to broker the sale. Astra Tech's dental implants, catheters, breathing aids and blood-management systems for surgery brought in about 3.9 billion Swedish crowns ($588 million) last year, and the unit employs around 2,200 staff. As part of its effort to jettison non-core businesses, AZ also seeks to sell a US chain of outpatient cancer centers called Aptium Oncology, which would likely fetch $500 million or less.

A survey of online promotion of drugs to professionals found that more than 150 brands used e-details and online events for the first time in 2010. Amgen's Prolia led the newbies with more than 7,600 online promotional activities during the first nine months of the year, said SDI, which produced the study. Merck's Dulera and AstraZeneca's Vimovo were right behind it with 6,100 and 4,100 activities, respectively. Overall, Merck's Singulair was tops in e-promotion, with 110,000-plus activities for the first nine months of 2010, followed by Pfizer's Pristiq, with 104,000 and Merck's Januvia with 89,000.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.